Plants extracts from Cameroon pharmacopeia strongly inhibit the Chikungunya virus infection by targeting entry and replication steps

Arginase inhibitory activities of chemical constituents from Macaranga hurifolia Beille leaves

The methanolic extract of the leaves of Macaranga hurifolia Beille showed arginase inhibitory activity (40% at 100 µg/mL) and was then fractionated to obtain nine polyphenolic compounds. Their structures were elucidated on the basis of NMR spectroscopic data, and by comparison with data previously reported in the literature, as gallic acid (1), 3,4-dihydroxybenzoic acid (2), chlorogenic acid, (3), corilagin (4), cynaroside (5), cosmosiin (6), hyperoside (7) isoquercitrin (8) and guajaverin (9). These compounds have been evaluated as arginase inhibitors. Compounds 4, 7, 8 and 9 showed varying arginase inhibitory activities with IC50 values ranging from 102 to 302 μM. All the isolated compounds were previously identified in this species but their activities on arginase are reported here for the first time.

Conjugates of ibuprofen inhibit CHIKV infection and inflammation

Chikungunya virus infection has become a global health concern because of its high rates of morbidity and mortality in patients with preexisting conditions. Inflammation and arthritis are the major symptoms of CHIKV that persist even after clearance of CHIKV. To develop an antiviral that can reduce infection and manage inflammation independent of the CHIKV infection, ibuprofen (IBU) conjugates with sulfonamide and thiosemicarbazide were synthesized. The conjugates, IBU-SULFA, IBU-ISS and IBU-IBT significantly inhibited CHIKV infection in vitro with a selectivity index (CC₅₀/IC₅₀) of > 11.9, > 25.1 and > 21, respectively. The reduction in infection was attributed to the interference of the conjugates in the early stages of CHIKV life cycle. With no acute oral toxicity, these compounds significantly reduced inflammation and arthritis in rats. Unlike IBU, the conjugates were not ulcerogenic. In conclusion, the conjugation imparted anti-CHIKV properties while retaining the anti-inflammatory properties of IBU. These findings can encourage further validation and research to develop an antiviral for CHIKV to manage both infection and arthritis.